NCT01596725已完成1 期
A Phase 1 Randomized, Observer-Blinded, Dose-Ranging Study to Evaluate the Immunogenicity and Safety of Monovalent A/Indonesia/05/05 (H5N1) Virus-Like Particle (VLP) Avian Influenza Antigen (Recombinant) in Healthy Young Adults With and Without Adjuvant 2.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Novavax
- 入组人数
- 333
- 试验地点
- 10
- 主要终点
- Number of solicited and unsolicited adverse events in H5N1 VLP antigen dose groups delivering HA with/without Adjuvant 2.
研究概览
简要总结
The purpose of this study is to evaluate the immunogenicity and safety profile of the Avian flu vaccine with and without adjuvant 2 in healthy, young adults. The study is divided down into Parts A1, A2 and B. Groups within each Part will receive two doses of the assigned test article on Study Days 0 and 21. There will be a Safety Monitoring Committee assessment following Day 7 for each part, prior to allowing vaccination of subjects in subsequent Parts of the study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 49 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy adult male or female, ≥18 and ≤49 years of age,
- •Willing and able to give informed consent prior to study enrollment,
- •Able to comply with study requirements, and
- •All women must have a negative urine pregnancy test prior to each vaccination. Women will be advised through the Informed Consent process to avoid becoming pregnant over the duration of the study, and must assert that they will employ an effective form of birth control for the duration of the study. Acceptable forms of birth control are: credible history of abstinence from heterosexual activity or prior surgical sterilization, hormonal contraceptives (oral, injectable, implant, patch, ring), double-barrier contraceptives (condom or diaphragm, with spermicide), and intrauterine device (IUD).
排除标准
- •Any ongoing, symptomatic acute or chronic illness requiring medical or surgical care. Asymptomatic conditions (e.g., hypertension, dyslipidemia) that are being managed medically and that are not associated with evidence of end-organ damage are not exclusionary provided they are clinically stable (defined as no unscheduled medical interventions or change in medications for cause within 3 months).
- •Any history of jaundice, or of hepatic injury due to drug (prescription, OTC, or illicit) or alcohol use or viral hepatitis; or the presence of hepatitis B surface antigen or hepatitis C antibody at screening.
- •Any grade 1 or higher (as based on the Toxicity Grading Scale [TGS]) abnormality in serum glutamic-pyruvic transaminase/alanine aminotransferase (SGPT/ALT), serum glutamic-oxaloacetic transaminase/aspartate aminotransferase (SGOT/AST), alkaline phosphatase, or total bilirubin levels.
- •Any grade 2 or higher (as based on the TGS) vital sign or clinical laboratory abnormality not specified in criterion 3 above. Note that any abnormal vital sign may be repeated at the Investigator's discretion.
- •Participation in research involving investigational product (drug / biologic / device) within 45 days before planned date of first vaccination.
- •History of a serious reaction to prior influenza vaccination.
- •History of Guillain-Barré Syndrome (GBS) within 6 weeks following a previous influenza vaccine.
- •Received any vaccine in the 4 weeks preceding the study vaccination; or any A/H5N1 avian influenza vaccine at any time.
- •Any known or suspected immunosuppressive condition, acquired or congenital, including HIV infection, as determined by history and/or physical examination.
- •Chronic administration (defined as more than 14 continuous days) of immunosuppressants or other immune-modifying drugs within 6 months prior to the administration of the study vaccine. An immunosuppressant dose of glucocorticoid will be defined as a systemic dose ≥10 mg of prednisone per day or equivalent. The use of topical, inhaled, and nasal glucocorticoids will be permitted.
- •Administration of immunoglobulins and/or any blood products within the 3 months preceding the administration of the study vaccine or during the study.
- •Acute disease at the time of enrollment (defined as the presence of a moderate or severe illness with or without fever, or an oral temperature >38.0°C on the planned day of vaccine administration).
- •Known disturbance of coagulation.
- •Women who are pregnant or breastfeeding, or plan to become pregnant during the study.
- •Suspicion or recent history (within one year of planned vaccination) of alcohol or other substance abuse.
- •Any condition that in the opinion of the investigator would pose a health risk to the subject if enrolled or could interfere with evaluation of the vaccine or interpretation of study results (including neurologic or psychiatric conditions deemed likely to impair the quality of safety reporting).
结局指标
主要结局
Number of solicited and unsolicited adverse events in H5N1 VLP antigen dose groups delivering HA with/without Adjuvant 2.
时间窗: Day 42
次要结局
- Measurement of HAI antibody seroconversion rates and GMT achieved by a constant H5N1 VLP antigen dose alone and in combination with Adjuvant 2.(Day 42)
研究者
研究点 (10)
Loading locations...
相似试验
已完成
1 期
A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 1Influenza (Pandemic)NCT01594320Novavax333
已完成
1 期
Safety Study of Avian Flu VaccineInfluenza A Virus, H5N1 SubtypeInfluenza A VirusInfluenzavirus AOrthomyxoviridaeH5N1 VirusNCT00408109National Institute of Allergy and Infectious Diseases (NIAID)45
已完成
1 期
Phase I Open-Label Study of Recombinant DNA Plasmid Vaccine, VRC-AVIDNA036-00-VP, Encoding for Influenza Virus H5 Hemagglutinin Protein Given IntradermallyInfluenza A Virus, H5N1 SubtypeInfluenza A VirusInfluenzavirus AOrthomyxovirdaeH5N1 VirusNCT00489931National Institute of Allergy and Infectious Diseases (NIAID)44
已完成
1 期
Safety and Immunogenicity Study of an Inactivated Influenza Vaccine (Whole Virion, Vero Cell Derived)InfluenzaNCT00289510Alachua Government Services, Inc.423
已完成
1 期
A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older AdultsInfluenza, HumanNCT06382311GlaxoSmithKline991